|Bid||79.69 x 100|
|Ask||81.28 x 500|
|Day's Range||81.29 - 82.57|
|52 Week Range||76.52 - 89.72|
|PE Ratio (TTM)||39.77|
|Forward Dividend & Yield||1.84 (2.26%)|
|1y Target Est||N/A|
CNBC contributor and former Medtronic CEO Bill George discusses health care consolidation and the latest deal between Cigna and Express Scripts.
A firestorm in cardiology resulted when a major NIN-funded clinical trial changed its design and moved the goalposts just before reaching completion.
Medical bills can cost hundreds of thousands of dollars in retirement, so it's important to have steady income coming in. Try these good dividend-paying stocks on for size.
Headquartered in Utica, New York, ConMed (CNMD) currently employs 3,100 people worldwide. In 4Q17, ConMed reported total sales close to $222.6 million, which represents a YoY (year-over-year) rise of ~7.9% on a CC (constant currency) basis and 9% on a reported basis, driven by the robust uptake of its products in the US and in international geographies. For fiscal 2017, ConMed reported total sales close to $796 million, which represents a YoY rise of ~4.3%, both on a CC and reported basis.
Medtronic, (MDT) presenting favorable results from the studies based on the CoreValve TAVR system might boost the top line, with increased uptake of the product.
Cash-rich businesses with sustainable and growing yields don't often go on sale, but we found 10 bargain stocks in the Morningstar US Dividend Growth Index.
On February 28, 2018, Medtronic (MDT) announced that it has entered into a partnership with LVHN (Lehigh Valley Health Network), an eight-hospital network. LVHN has a presence in seven counties in Northeastern Pennsylvania.
On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3, the latest and most accurate CGM (continuous glucose monitoring) sensor. The expanded indication will enable the sensor to be worn on the upper arm, thus providing more flexibility, higher accuracy, and enhanced performance. It is the only sensor approved for use with Medtronic’s MiniMed 670G, which is the first HCL (hybrid closed loop) insulin delivery system in the world.
On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set, the newest addition to its portfolio of MiniMed infusion sets. The device is used for insulin delivery from an insulin pump to a person’s body. In late 2018, Medtronic plans to expand the commercial availability of the device in other geographies around the world.
The outlook for the US medical products and devices industry has been revised upward, to positive from stable, Moody's Investors Service says in a just-published report. Continued product innovation and ...
As of March 7, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 20.8x, while the stock has a PE ratio of 59x. The forward estimate is lower than the current PE ratio, which reflects the analysts’ expectations for higher company earnings over the next 12 months. To calculate the forward PE for a company, the current stock price of the company is divided by its earnings estimates for the next 12 months.
On March 6, 2018, Abbott Laboratories (ABT) announced that it received FDA (US Food and Drug Administration) approval for its Masters HP 15-mm rotatable mechanical heart valve, which is the first and only heart valve developed for newborns and infants. The trial included patients five years and under who had damaged, diseased, or malfunctioning heart valves. On March 6, 2018, ABT stock rose ~0.86%, whereas Medtronic (MDT), Boston Scientific (BSX), and Edwards Lifesciences (EW), which are the other major players in the structural heart device business, saw gains of ~0.83%, ~0.04%, and ~1.2%, respectively.
On February 27, 2018, Abbott Laboratories (ABT) and Surmodics (SRDX) announced that the two companies have entered an agreement for the commercialization rights of Surmodics’ SurVeil DCB (drug-coated balloon) for the treatment of superficial femoral artery. As per the agreement, Abbott Laboratories will gain exclusive commercial rights for the SurVeil DCB, which is currently in clinical trials. Surmodics will supply the device to Abbott once approved.
On February 26, 2018, Stryker (SYK) closed trading at $165.77. According to Stryker, it has delivered sales growth consistently higher than that of the average performance of the medical technology industry over the past several years. The stock is currently trading above its 200-day moving average of $160.03 and its 50-day moving average of $160.03.